Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Information of ATCC cell lines</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Seung Yeon Oh (15051017) (author)
Drugi avtorji:	You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Table S5 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
od: Nina Müller (16721126)
Izdano: (2025)

Table S6 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
od: Nina Müller (16721126)
Izdano: (2025)

Table S7 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
od: Nina Müller (16721126)
Izdano: (2025)

Table S8 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
od: Nina Müller (16721126)
Izdano: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
od: Nicole A. Traphagen (16677391)
Izdano: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
od: Nicole A. Traphagen (16677391)
Izdano: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
od: Phyllis S.Y. Chong (17141520)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_66c2pcv0hk7jvl4jabe2d0m1g9